| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
There are few useful biomarkers for early diagnosis of lung cancer. Therefore most patients with lung cancer are at an advanced stage at the time of diagnosis. To obtain useful diagnostic markers for lung adenocarcinoma, we generated monoclonal antibodies using exosomal proteins from lung adenocarcinoma-derived A549 cells by employing the random immunization method. To evaluate the utility of these antibodies as differential diagnostic marker and/or sero-diagnostic marker for lung adenocarcinoma, we performed immunohistochemical study with tissue microarray and dotblot analysis with sera from lung cancer patients and normal controls. As the results, we successfully obtained the candidate biomarkers for diagnosis of lung adenocarcinomas.
|
